Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Haemophilia A (EU5) 2019

Product Code:
Publication Date:
May 2019

What are the market access obstacles that are shaping the EU5 haemophilia A market and which brands are winning out?

  • How are market barriers affecting haemophilia A drug prescribing?
  • How do market barriers affect the market share of leading brands?
  • What specific market access barriers are challenging each brand?
  • Which brands gain and lose the most market share due to market barriers?

High cost, no formulary listing and stock availability are just some of the barriers that can negatively influence prescribing volumes and exert downward pressure on profitability. What market access barriers are influencing physicians’ therapy choices and how is this determining market share?

This and other key questions are answered in this insightful May 2019 analysis of 13 leading haemophilia A brands. Based on the results of an in-depth survey of 150 EU5-based haematologists, Market Access Impact (EU5): Haemophilia A identifies the market access barriers that are shaping the competitive landscape for leading rheumatoid arthritis brands in the EU5 and provides clear pointers for management action.

Buy Now

Buy and Download this report

Evaluating leading companies in the EU5 haemophilia A sector

  • Bayer
  • CSL Behring
  • Grifols
  • Novo Nordisk
  • Octapharma
  • Pfizer
  • Roche
  • Shire
  • Swedish Orphan Biovitrum

Leading brands covered in this report

  • Advate (octocog alfa; Shire)
  • Adynovate (rurioctocog alfa pegol; Shire)
  • Alphanate (factor VIII/von Willebrand factor concentrate; Grifols)
  • Eloctate (efmoroctocog alfa; Bioverativ/Sanofi)
  • Feiba (Anti-Inhibitor Coagulant Complex; Shire)
  • Hemlibra (emicizumab-kxwh; Roche)
  • Humate-P (Antihemophilic Factor/von Willebrand Factor Complex [Human]; CSL Behring)
  • Helixate FS (octocog alfa; CSL Behring)
  • Kovaltry (octocog alfa; Bayer)
  • Jivi (damoctocog alfa pegol; Bayer)
  • NovoEight (turoctocog alfa; Novo Nordisk)
  • Nuwiq (simoctocog alfa; Octapharma)
  • Xyntha (moroctocog alfa; Pfizer)

Answering important market access questions

  • What underpins the physicians’ prescribing of Humate-P, Advate and Feiba?
  • What is the overall impact of market barriers on prescribing?
  • Not available on formulary? Not recommended in guidelines? Limited availability? What market access obstacles are impacting NovoEight, Nuwiq and Xyntha?
  • How many market barriers are impacting Hemlibra, Jivi and Eloctate?
  • How are market access issues impacting the market shares of Advate, Adynovate and Alphanate, and which competitor brands are benefitting?

Market access barriers examined in this survey

  • Not available on formulary
  • Too expensive
  • Not recommended by guidelines
  • Limited availability
  • Patients prefer other medications
  • Only recommended for certain patient types
  • Is not reimbursable

Exclusive to FirstView, Market Access Impact surveys reveal the barriers that influence prescribing, identify the brands that win or lose market share, and highlight the
brand-specific market access challenges that management must overcome

The experience of the physicians surveyed

This detailed analysis is based on a survey of 150 EU5 haematologists with a wealth of experience treating haemophilia A. On average they:

  • Saw 34 patients the month preceding the survey
  • Have 17 years in practice
  • Have prescribed at least one of the brands assessed

This report gives you...

  • Practical data to understand how market barriers impact the prescribing decisions haematologists treating haemophilia A make
  • 33 clear, easy-to-read, charts that provide at-a-glance understanding of the survey findings
  • Actionable and detailed information identifying specific areas where medical access teams can improve brand share

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Buy Now

Buy and Download this report

Other HAEMOPHILIA A reports available

Market Access Impact (US): Haemophilia A

Medical Affairs Reputations (US): Haemophilia A

Medical Affairs Reputations (Europe): Haemophilia A

NPS+ US: Haemophilia A

NPS+ Europe: Haemophilia A

Therapy Trends KOL Insight: Haemophilia A

To learn about our cost effective intelligence package of all Haemophilia A reports, please contact us at info@fwreports.com


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved